Akorn
As of the edition of 20 October 2026, Akorn runs 13 drugs, 13 of them marketed.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
Akorn was bankrupt in 2020.
- Akorn, Inc.: bankrupt in 2020
Drugs by status
| Status | Count |
|---|---|
| Marketed | 13 |
| Total | 13 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Lidocaine | none listed | 2 |
| Hydrocortisone | none listed | 5 |
| Indocyanine green acid form | none listed | 0 |
| Heparin | none listed | 5 |
| Phenylephrine | none listed | 6 |
| Atropine | none listed | 12 |
| Ephedrine | none listed | 9 |
| Hyaluronidase | none listed | 0 |
| Fluorescein | none listed | 0 |
| Heparin sodium | none listed | 3 |
| Hydroxyprogesterone caproate | none listed | 1 |
| Hydrocortisone acetate | none listed | 2 |
| Dimercaprol | none listed | 0 |
A route B row is one company at one target.